List of Excipients in Branded Drug UTIBRON NEOHALER

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sunovion Pharmaceuticals Inc	UTIBRON NEOHALER	indacaterol maleate and glycopyrrolate	63402-681	LACTOSE MONOHYDRATE	2028-10-11
Sunovion Pharmaceuticals Inc	UTIBRON NEOHALER	indacaterol maleate and glycopyrrolate	63402-681	MAGNESIUM STEARATE	2028-10-11

Utibron Neohaler Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: July 31, 2026

Utibron Neohaler is a dry-powder inhaler combining indacaterol maleate, a long-acting beta-2 adrenergic agonist, with glycopyrrolate, a long-acting muscarinic antagonist. Its commercial formulation uses lactose monohydrate as the principal carrier excipient in single-dose capsules administered through the Neohaler device. The strongest commercial opportunities are generic dry-powder inhaler development, carrier-engineered lactose, capsule and device supply, regional reformulation, and lifecycle products that improve dose uniformity or ease of use.

Utibron was approved by the U.S. Food and Drug Administration in October 2015 for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. It is not indicated for acute bronchospasm relief. The product is a small-molecule combination, so biosimilar competition is not relevant. Generic competition depends on abbreviated new drug application, or ANDA, approvals, Orange Book patent listings, product discontinuation status, and the ability to demonstrate pharmaceutical equivalence through a complex inhalation-device program. [1]

What is the Utibron Neohaler formulation?

Utibron Neohaler delivers indacaterol and glycopyrrolate as a dry powder contained in capsules for inhalation. The patient places a capsule into the Neohaler device, punctures the capsule, and inhales the powder.

Product attribute	Utibron Neohaler
Active ingredients	Indacaterol maleate and glycopyrrolate
Dosage form	Capsule-based dry powder for inhalation
Strength	27.5 mcg glycopyrrolate and 15.6 mcg indacaterol per capsule
Administration	Two inhalations from one capsule, once daily
Device	Neohaler inhaler
Primary excipient	Lactose monohydrate
Therapeutic category	Long-acting dual bronchodilator for COPD
FDA application	NDA 207930
Approval date	October 29, 2015
Reference sponsor	Novartis Pharmaceuticals Corp.
U.S. regulatory pathway for competitors	ANDA or, in some cases, 505(b)(2)

The product’s label identifies lactose monohydrate as an inactive ingredient. The capsule is a delivery container rather than a conventional oral dosage form. The formulation must control powder dispersion, emitted dose, aerodynamic particle-size distribution, capsule emptying, and chemical stability during storage. [1]

Which excipient is used in Utibron Neohaler?

Lactose monohydrate is the principal excipient used in Utibron Neohaler. In carrier-based dry-powder inhalers, lactose performs several functions:

• It provides bulk for very low-dose active ingredients.
• It improves powder handling during blending and filling.
• It reduces segregation between the active pharmaceutical ingredients and carrier particles.
• It supports reproducible metering from the capsule.
• It helps generate an inhalable fine-particle fraction when active particles detach during inhalation.

The active ingredients are present at microgram quantities, while the lactose carrier represents the dominant powder mass. This creates a formulation challenge: minor changes in lactose particle size, surface morphology, moisture, or fines content can alter dose delivery.

Why lactose grade matters

Generic developers cannot treat lactose as a commodity input without process qualification. Relevant attributes include:

Lactose attribute	Commercial impact
Particle-size distribution	Controls blend uniformity and powder dispersion
Fine-particle fraction	Affects active adhesion and detachment
Surface roughness	Influences drug-carrier interaction
Crystallinity	Affects stability and moisture response
Residual moisture	Can change cohesion and chemical stability
Bulk density	Influences capsule fill weight and emitted dose
Microbial quality	Affects inhalation-product compliance
Supplier consistency	Determines batch-to-batch reproducibility

A carrier strategy based on one lactose grade may simplify development but creates supply-chain concentration. A multi-supplier strategy improves resilience but requires bridging data and tight control of critical material attributes.

What excipient strategy is optimal for Utibron generic development?

The most practical strategy is a lactose-based carrier system with active-particle engineering and a controlled coarse-carrier/fine-lactose balance. The objective is not simply to match the reference product’s qualitative formula. The developer must reproduce the drug product’s critical performance characteristics.

Strategy 1: Use inhalation-grade lactose with controlled fines

A coarse lactose carrier can provide bulk and flow, while lactose fines occupy surface sites and help regulate active-particle adhesion. Excess fines can increase cohesion and reduce dispersibility. Too few fines can produce poor blend uniformity or excessive active retention on the carrier.

A development program should screen:

1. At least two inhalation-grade lactose particle-size distributions.
2. Multiple fines levels.
3. Different blending energies and blending times.
4. Active-to-carrier ratios for both indacaterol and glycopyrrolate.
5. Powder performance at low, medium, and high inspiratory flow rates.

Strategy 2: Engineer the active particles

Indacaterol and glycopyrrolate require aerodynamic particle sizes generally suitable for lung deposition. Micronization, spray drying, controlled crystallization, or surface modification can change emitted dose and fine-particle dose without changing the nominal excipient composition.

The commercial tradeoff is direct:

• Micronization is familiar and scalable but can increase cohesion and electrostatic charging.
• Spray drying allows engineered morphology but adds process complexity.
• Co-micronization can improve content uniformity but may create segregation or stability issues.
• Surface treatment can improve aerosolization but may increase regulatory and patent risk.

Strategy 3: Evaluate alternative carriers selectively

Potential alternatives include mannitol, trehalose, or engineered composite carriers. These systems may improve moisture tolerance or avoid direct dependence on lactose, but they introduce new regulatory questions. A lactose-free formulation may require more extensive comparative evidence because lactose is part of the established reference-product formulation and is widely accepted in inhalation products.

Alternative carriers are more attractive for:

• New-device products.
• Regional products where lactose intolerance concerns influence marketing.
• Reformulations with improved humidity resistance.
• Products using spray-dried or carrier-free particles.
• Combination products seeking differentiated intellectual property.

What formulation patents protect Utibron Neohaler?

Protection for Utibron is likely distributed across several patent categories rather than one excipient patent:

Protection category	Relevance to Utibron
Chemical composition	Indacaterol and glycopyrrolate combination
Salt and polymorph claims	Active-ingredient forms and solid-state properties
Combination therapy	Use of both bronchodilators in COPD
Dosage regimen	Once-daily administration and dose ranges
Dry-powder formulation	Powder composition, particle characteristics, and performance
Capsule delivery	Single-dose capsule configuration
Inhaler device	Neohaler operating structure and airflow design
Manufacturing	Micronization, blending, filling, and dose-control processes
Method of treatment	Maintenance treatment of airflow obstruction

For a generic developer, the key distinction is between patents listed in the FDA Orange Book and patents enforceable outside the Orange Book. Orange Book-listed patents can trigger Paragraph IV certification and a potential 30-month stay if the patent holder files suit within the statutory period. Device, manufacturing, and formulation rights may still create commercial risk even when they are not listed as drug-substance or drug-product patents. [2]

How strong is the Utibron patent estate?

The estate is stronger from a technical-development perspective than from a conventional small-molecule composition perspective. The product combines two established active ingredients in a capsule-based inhaler. A competitor may avoid some composition claims by using different particle engineering, excipient grades, capsule materials, or inhaler architecture. It may not be able to avoid comparative performance requirements.

The most meaningful barriers are likely to be:

• Demonstrating equivalent delivered dose.
• Matching aerodynamic particle-size distribution.
• Reproducing capsule emptying and device resistance.
• Establishing equivalence for both active ingredients.
• Controlling dose uniformity across the labeled flow-rate range.
• Avoiding device and formulation patent claims.
• Building an adequate human-factors package for a substitute inhaler.

When does Utibron lose exclusivity?

Utibron’s principal U.S. regulatory exclusivity was not expected to provide a long-term barrier comparable with biologic exclusivity. The product received standard new-chemical-entity exclusivity treatment only to the extent applicable to its active ingredients and combination regulatory status. Because indacaterol and glycopyrrolate had prior regulatory histories in other products and jurisdictions, the commercial entry date is controlled primarily by patent rights and ANDA readiness rather than by an extended biologic-style exclusivity period.

A precise generic-entry date depends on the Orange Book’s active patent listings and any litigation, settlement, pediatric extension, or regulatory exclusivity. Patent expiration should be confirmed against the current FDA Orange Book rather than inferred from the 2015 approval date. [2]

What is the Orange Book status of Utibron?

Utibron is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations database under its NDA. The Orange Book identifies patents and exclusivity information that FDA considers relevant to approval of therapeutically equivalent drug products. Its listing status does not establish that every device, manufacturing, formulation, or foreign patent has expired.

For commercial diligence, the relevant checks are:

• Whether NDA 207930 remains listed as a reference standard.
• Whether the product is identified as currently marketed or discontinued.
• Which patents remain active in the Orange Book.
• Whether any pediatric exclusivity or other regulatory period applies.
• Whether approved ANDAs have been listed.
• Whether any applicant has filed a Paragraph IV certification.
• Whether patent litigation has triggered a 30-month stay.

Are companies challenging Utibron with Paragraph IV filings?

A Paragraph IV challenge is the standard pathway for an ANDA applicant that asserts an Orange Book patent is invalid, unenforceable, or not infringed. Publicly available FDA and federal court records should be reviewed together because an ANDA filing may not produce immediate litigation, and a court dispute may involve patents that are not the only commercial barriers.

No biosimilar pathway applies to Utibron. Any competitive challenge would be a generic or hybrid small-molecule inhalation product.

The principal Paragraph IV risk factors are:

Risk factor	Effect on entry
Active listed formulation patent	Can delay approval or launch
Device patent	May require a non-infringing inhaler
Patent litigation	Can create a 30-month stay
Non-listed manufacturing patent	May require process redesign
Reference-product discontinuation	Can affect ANDA reference strategy
Device substitution	May increase clinical and human-factors burden
Complex equivalence testing	Can delay approval after patent clearance

What regulatory pathway applies to a Utibron generic?

A conventional ANDA is the likely pathway when the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. Inhalation products create more demanding equivalence questions than standard tablets or capsules.

The development package may need to address:

• Same active ingredients and strengths.
• Same dosage form and route of administration.
• Equivalent delivered dose.
• Equivalent fine-particle dose.
• Comparable aerodynamic particle-size distribution.
• Comparable single-dose and batch-to-batch performance.
• Device functionality and resistance.
• Labeling and user instructions.
• Human-factors considerations for the inhaler.
• Stability under relevant temperature and humidity conditions.

FDA product-specific guidance for orally inhaled and nasal drug products is central to the development strategy. FDA may accept an alternative device in some circumstances, but a different inhaler can create additional equivalence and usability requirements. [3]

What commercial opportunities exist for Utibron excipients?

Inhalation-grade lactose supply

The clearest near-term opportunity is supply of qualified lactose monohydrate with documented particle-size distribution, moisture control, low bioburden, and consistent surface properties. A supplier can compete through:

• Narrower particle-size specifications.
• Better control of fines.
• Dual-site manufacturing.
• Lot-to-lot comparability packages.
• Regulatory support for ANDA submissions.
• Supply agreements with generic inhaler developers.

The value is higher than the price of ordinary pharmaceutical lactose because inhalation-grade material is tied to aerodynamic performance and equivalence risk.

Engineered carrier platforms

Engineered lactose particles with controlled surface morphology can support improved dispersibility and dose uniformity. Commercial licensing opportunities include proprietary carrier grades, co-processing methods, and carrier-treatment technologies.

The strongest business model is usually a development partnership rather than a standalone excipient sale. The supplier can provide formulation screening, analytical methods, device testing, and regulatory documentation.

Low-moisture and humidity-resistant systems

COPD patients may use inhalers in variable environmental conditions. A powder with better moisture tolerance can reduce dose variability and improve product robustness. Opportunities include:

• Low-hygroscopic carriers.
• Moisture-barrier capsule packaging.
• Desiccant-integrated blister or pouch systems.
• Device designs that limit ambient humidity exposure.
• Coated or engineered lactose particles.

Capsule and packaging systems

Capsule suppliers can compete through low-fragmentation inhalation capsules, controlled puncture behavior, low electrostatic charging, and consistent emptying. Packaging suppliers can differentiate through high-barrier foil, unit-dose protection, and improved resistance to humidity ingress.

Reformulated combination products

A reformulation could use a different inhaler, a new capsule system, or a carrier-free powder. Possible commercial claims include improved portability, lower residual powder, reduced priming, simpler loading, or more consistent performance across inspiratory flow rates. These products may require a 505(b)(2) application rather than an ANDA if they cannot meet the reference-product equivalence framework.

How does Utibron compare with competing COPD inhalers?

Utibron competes with other long-acting dual bronchodilators, including umeclidinium/vilanterol, tiotropium/olodaterol, and aclidinium/formoterol products. Its commercial position depends on once-daily dosing, the Neohaler capsule workflow, payer coverage, physician familiarity, and the broader shift toward fixed-dose long-acting maintenance therapy.

Product	Active ingredients	Device/form	Commercial relevance
Utibron Neohaler	Indacaterol/glycopyrrolate	Capsule dry powder	Dual bronchodilation; once daily
Anoro Ellipta	Umeclidinium/vilanterol	Blister dry powder	Integrated device; once daily
Stiolto Respimat	Tiotropium/olodaterol	Soft-mist inhaler	Once daily; different delivery platform
Bevespi Aerosphere	Glycopyrrolate/formoterol	Metered-dose inhaler	Dual bronchodilation; different device
Duaklir Pressair	Aclidinium/formoterol	Dry-powder inhaler	Twice-daily maintenance option

The competitive threat is not limited to a direct Utibron generic. A lower-cost competing long-acting dual bronchodilator can reduce utilization even without substituting at the pharmacy-counter level.

What revenue exposure does Utibron create?

Utibron’s revenue exposure is concentrated in the COPD maintenance market. Public reporting generally aggregates respiratory products within broader company portfolios, limiting standalone revenue analysis. The main commercial variables are:

• COPD prevalence and diagnosis rates.
• Use of long-acting dual bronchodilators.
• Generic substitution.
• Formulary positioning.
• Device adherence.
• Combination-product pricing.
• Availability of alternative LABA/LAMA products.

For an excipient or device supplier, the addressable opportunity is broader than Utibron sales. The same lactose, capsule, moisture-control, and powder-engineering platform can support other inhaled bronchodilators, corticosteroid combinations, and generic dry-powder products.

What generic launch scenarios exist for Utibron?

Scenario 1: Direct Neohaler-compatible generic

This route offers the closest substitution opportunity. It requires a capsule and device system that satisfies equivalence and intellectual-property requirements. It also creates dependence on device tooling and a narrow formulation design space.

Scenario 2: Alternative-device 505(b)(2) product

An alternative inhaler may permit differentiated handling, packaging, or dose delivery. The regulatory burden is higher, but the product may avoid some device claims and compete through usability.

Scenario 3: Regional lactose-based product

Markets outside the United States may accept different device and equivalence packages. A regional product can use established lactose technology with local regulatory adaptation, subject to national patent and data-exclusivity rules.

Scenario 4: Carrier-free or spray-dried reformulation

This approach can support a differentiated patent position and potentially improved aerosolization. It requires greater process development, stability work, and regulatory investment.

What manufacturing and IP barriers affect commercial entry?

Manufacturing barriers include low-dose blend uniformity, segregation during capsule filling, active-particle agglomeration, electrostatic charging, capsule puncture variability, and humidity sensitivity. These issues can cause batch failures even when the nominal composition is simple.

The highest-value intellectual property opportunities are likely to cover:

• Engineered lactose morphology.
• Active-carrier surface interactions.
• Co-micronized active combinations.
• Capsule filling and powder retention controls.
• Humidity-resistant packaging.
• Alternative inhaler airflow paths.
• Dose-counting and capsule-emptying mechanisms.
• Manufacturing processes that improve fine-particle dose.

A patent strategy should separate claims directed to the powder from claims directed to the capsule, device, packaging, and manufacturing process. This creates multiple licensing and enforcement positions and can reduce dependence on a single formulation patent.

Key Takeaways

• Utibron Neohaler uses lactose monohydrate as its principal powder carrier.
• The commercial formulation challenge is aerodynamic performance, not excipient novelty alone.
• Inhalation-grade lactose with controlled fines, moisture, and surface properties is the most direct excipient opportunity.
• Generic competition is governed by ANDA requirements, Orange Book patents, device performance, and inhalation-product equivalence.
• Biosimilar risk does not apply because Utibron is a small-molecule combination product.
• Alternative-device, carrier-free, and humidity-resistant formulations offer higher differentiation but carry greater regulatory and development costs.
• Capsule, packaging, lactose, particle-engineering, and device suppliers can sell into a broader COPD inhaler market rather than relying solely on Utibron volume.
• Patent diligence must cover Orange Book listings, device rights, formulation claims, manufacturing patents, and settlement or litigation records.

FAQs

Can lactose monohydrate be replaced in a Utibron generic inhaler?

Yes, but a substitute carrier may require a different equivalence strategy and could increase regulatory risk. Lactose remains the lowest-risk starting point because it is established in the reference formulation and widely used in dry-powder inhalers.

Is Utibron a biologic or biosimilar product?

No. Utibron contains the small molecules indacaterol and glycopyrrolate. Competition would proceed through generic-drug pathways, not the biosimilar pathway under the Public Health Service Act.

Does an Utibron generic need to use the Neohaler device?

Not necessarily. A generic developer may pursue a device that meets applicable equivalence requirements, but a different inhaler can increase device, human-factors, and regulatory complexity.

Which excipient supplier characteristics matter most for Utibron development?

The most important characteristics are consistent particle-size distribution, controlled fines, low moisture, low bioburden, stable surface morphology, reliable supply, and regulatory documentation suitable for an inhalation product.

Can a lactose-free Utibron reformulation obtain separate patent protection?

Yes. A lactose-free or carrier-free powder may support formulation, particle-engineering, device, or manufacturing claims. Patentability depends on technical distinctions, unexpected performance, claim scope, and prior art.

References

1. U.S. Food and Drug Administration. (2015). Utibron Neohaler prescribing information. Novartis Pharmaceuticals Corporation.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2022). Bioequivalence studies for orally inhaled drug products submitted in ANDAs: Guidance for industry. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2015). FDA approves Utibron Neohaler for chronic obstructive pulmonary disease. https://www.fda.gov/

5. Global Initiative for Chronic Obstructive Lung Disease. (2024). Global strategy for the prevention, diagnosis and management of chronic obstructive pulmonary disease. GOLD.